Friday 6 November 2026
Export SINT’s income statement to Excel — free account
SINTX TECHNOLOGIES, INC.
SINT Healthcare Medical Devices
SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024.
- Revenue
- +952.9%
- EPS
- +93.1%
- Free cash flow
- +47.4%
- Total debt
- −6.78%
Quarter to September 2026, against a year earlier
1.56
0.06
−3.70%
Follow SINT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(500.75%) | (503.49%) | (429.26%) | 0.00% | |
Piotroski F-Score |
2 | 2 | 2 | — | |
| (180.59%) | (182.89%) | (192.88%) | 0.00% | ||
ROIC |
0.00% | 0.00% | (548.06%) | (436.11%) | |
Return on Tangible Assets |
(713.87%) | (3,106.17%) | (422.27%) | 0.00% | |
Average Days of Receivables |
63.82 | 129.12 | 90.29 | 14.44 | |
Free Cash Flow per Share |
(3.03) | (2.38) | (2.13) | (1.35) | |
Free Cash Flow |
(8.41) | (9.54) | (10.34) | (8.97) | |
Capital Expenditures |
0.16 | 0.22 | (0.22) | — | |
| Other line items | |||||
Cash ROIC |
(118.82%) | (329.15%) | (121.29%) | (164.61%) | |
Accounts Receivable Turnover |
5.44 | 4.46 | 6.24 | 26.39 | |
Accounts Payable Turnover |
1.64 | 1.08 | 1.12 | 2.30 | |
Inventory Turnover |
0.84 | 0.60 | 0.48 | 0.89 | |
Average Days of Payables |
250.32 | 381.01 | 543.72 | 261.76 | |
Days of Inventory on Hand |
540.62 | 930.18 | 1,310.97 | 695.95 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
450.59% | 372.69% | 238.35% | 74.09% | |
Selling, General and Administrative Expense of Revenue |
632.51% | 780.76% | 690.90% | 284.39% | |
Share Based Compensation of Revenue |
196.07% | 228.28% | 182.11% | 55.40% | |
Interest Coverage |
(206.17) | (226.37) | (301.74) | (358.86) | |
Operating CF/Net income |
0.50 | 0.55 | 0.53 | 0.00 | |
Depreciation/Fixed assets |
1.39 | 1.51 | 1.45 | 0.00 | |
Capex/Depreciation |
0.25 | 0.35 | (0.34) | — | |
Revenue per Share |
0.37 | 0.26 | 0.27 | 0.50 | |
Operating CF per Share |
(3.09) | (2.43) | (2.09) | (1.35) | |
Capex per Share |
0.06 | 0.05 | (0.04) | 0.00 | |
Capex to Sales |
(0.16) | (0.21) | 0.16 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026